Targeted inhibition of Rmrp in AEC‐II or AMs offers a promising strategy for alleviating SII and preventing secondary pneumonia, paving the way for novel therapeutic interventions in sepsis management. Here, RMRP is linked to susceptibility to pneumonia measurement.